Kavain

Template:Chembox image cellTemplate:Chembox image cellTemplate:Chembox AllOtherNamesTemplate:Chembox headerbarTemplate:Chembox IndexlistTemplate:Chembox JmolTemplate:Chembox ChEMBLTemplate:Chembox ECHATemplate:Chembox E numberTemplate:Chembox IUPHAR ligandTemplate:Chembox UNIITemplate:Chembox CompToxTemplate:Chembox headerbarTemplate:Chembox Datapage checkTemplate:Yesno

Kavain

Template:Longitem	Template:Unbulleted list
ChEBI	Template:Unbulleted list
ChemSpider	Template:Unbulleted list
DrugBank	Template:Unbulleted list
EC Number	Template:Unbulleted list
KEGG	Template:Unbulleted list
Template:Longitem	Template:Unbulleted list
RTECS number	Template:Unbulleted list
Template:Longitem	Template:Chembox Elements/molecular formula
Molar mass	Template:Chem molar mass

Kavain is the principal kavalactone found in the roots of the kava plant (Piper methysticum), where it contributes significantly to the plant’s psychoactive and anxiolytic effects.

Kavain exhibits anticonvulsant properties by modulating voltage-dependent sodium and calcium channels, and it may influence mood and anxiety through reversible inhibition of monoamine oxidase A and monoamine oxidase B, potentially affecting serotonin, dopamine, and norepinephrine signaling. Although it does not bind to the benzodiazepine site of GABAA receptors, kavain potentiates GABA activity at extrasynaptic α4β2δ GABAA receptors and overlaps with the modulatory pathways of certain general anesthetics. It also shows weak sodium antagonism, strong L-type calcium channel blockade, and enhances early potassium currents, suggesting mood-stabilizing effects akin to lamotrigine.

Its precise mechanisms remain under investigation, but its activity across multiple pathways makes it a promising candidate for drug development targeting ion channels, P-glycoprotein, cytochrome P450, and cyclooxygenase enzymes.

Pharmacology

Kavain has anticonvulsive properties, attenuating vascular smooth muscle contraction through interactions with voltage-dependent [[Sodium channel|Template:Chem2]] and Template:Chem2 channels. How this effect is mediated, and to what extent this mechanism is involved in the anxiolytic and analgesic effects of kavalactones on the central nervous system, is unknown. The recent finding that kavain can reversibly inhibit both monoamine oxidase A and monoamine oxidase B suggests that kavain may exert some of its effects by modulating serotonin, norepinephrine, and dopamine signaling.

However, the precise mechanisms underlying the psychotropic, sedative, and anxiolytic actions of kavain and related kavalactones are still debated. Direct binding to the benzodiazepine/flumazenil binding site of the GABA-A receptor does not occur with kavain enantiomers. Many studies involved kava extracts from different plant parts and are, therefore, not applicable to kavain itself. Kavain directly modulates several human GABA_A receptor subtypes—most strongly α4β2δ—via a mechanism independent of the classical benzodiazepine binding site; its reduced efficacy at receptors carrying the β3N265M anesthetic-resistance mutation suggests overlap with the modulatory pathways of certain general anesthetics.

A comparative review of in-vivo studies with kavain (and related kavapyrones) to commonly used antiepileptic drugs and mood stabilizers affecting ion fluxes indicates that the kavapyrones are weakly Na+ antagonistic and therefore antiepileptic. They also have pronounced [[L-type calcium channel|L- type Template:Chem2 channel]] antagonistic properties and act as a positive modulator of the early K+ outward current, which contribute to mood stabilizing properties similar to lamotrigine.

Kavain and analogs remain interesting for drug discovery against a variety of cellular targets, including P-glycoprotein (Pgp), cytochrome P450, and cyclo-oxygenase (COX) enzymes among others.

See also

• 5,6-dehydrokavain